The Contemporary Use of Radium-223 in Metastatic Castration-resistant Prostate Cancer.
Sign Up to like & getrecommendations! Published in 2017 at "Clinical genitourinary cancer"
DOI: 10.1016/j.clgc.2017.08.020
Abstract: Radium-223 dichloride (radium-223) was approved for the treatment of patients with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases in the United States and Europe in 2013. This followed a reported overall survival benefit for… read more here.
Keywords: radium; radium 223; prostate cancer; use radium ... See more keywords